Le Lézard
Classified in: Health
Subjects: RCL, CFG

Food Recall Warning (Allergen) - Valentine Eruption Cake sold by Save-On-Foods recalled due to undeclared almonds and walnuts


Product photos are available at: https://bit.ly/3s8GByk 

OTTAWA, ON, Feb. 19, 2021 /CNW/ - Save-On-Foods is recalling Valentine Eruption Cake from the marketplace because it contains almonds and walnuts which are not declared on the label. People with an allergy to almonds or walnuts should not consume the recalled product described below.

The following product has been sold in Manitoba, Saskatchewan, Alberta, British Columbia, and Yukon.

Recalled product

Brand

Product

Size

UPC

Codes

None ? sold by Save-on-Foods

Valentine Eruption Cake

325 g

0 062639 454456

All best before dates up to and including 2021.FE.23

What you should do

Check to see if you have the recalled product in your home. Recalled products should be thrown out or returned to the store where they were purchased.

If you have an allergy to almonds or walnuts, do not consume the recalled product as it may cause a serious or life-threatening reaction.

Background

This recall was triggered by the company. The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated Food Recall Warnings.

The CFIA is verifying that industry is removing the recalled product from the marketplace.

Reactions

There have been reported reactions associated with the consumption of this product.

SOURCE Canadian Food Inspection Agency (CFIA)


These press releases may also interest you

at 04:00
Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global clinical trials industry, today announced the launch of SUBMIT24 in its beta version during Q3 2024,...

at 04:00
TVM Capital Healthcare, a specialist healthcare private equity firm headquartered in Dubai and...

at 03:26
Calliditas Therapeutics AB , ("Calliditas") today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine...

at 03:00
Flindr...

at 03:00
CSL Vifor and Travere Therapeutics, Inc., today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the...

at 03:00
Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies' pipeline candidates. The...



News published on and distributed by: